Eli Lilly: William G. Kaelin Jr. receives 168-share grant
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Eli Lilly & Co. director William G. Kaelin Jr. acquired 168 common shares in a grant or award on November 16, 2026. A per-share amount of $1,431.67 was reported. His direct holdings after the transaction were 22,139 shares.
Insider Trade Summary
Grant/Award: 167.6364 shares
Grant/Award
1 txn
Insider
Kaelin William G Jr
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 167.6364 | $1,431.67 | $240K |
Holdings After Transaction:
Common Stock — 22,139.3689 shares (Direct)
Holdings Before and After:
Common Stock, 21,971.7325 to 22,139.3689 shares (Direct)
Key Figures
Shares acquired: 168 shares
Reported per-share amount: $1,431.67 per share
Direct holdings after transaction: 22,139 shares
3 metrics
Shares acquired
168 shares
Common stock acquired in a grant or award on November 16, 2026
Reported per-share amount
$1,431.67 per share
Common stock grant or award on November 16, 2026
Direct holdings after transaction
22,139 shares
Common stock following the November 16, 2026 transaction
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.